Adocia disclosed additional results on AdoShell Islets during recent international congresses. Islet transplantation has long been recognized as an effective treatment for Type 1 Diabetes (T1D). However, the limitations imposed by the requirement for immunosuppression have hindered its widespread application.

Adocia has set out to overcome this hurdle and has developed AdoShell Islets, an implantable and fullyretrievable scaffold for islet transplantation that eliminates the need for immunosuppression drugs while ensuring the success of the transplantation procedure. AdoShell is based on a permselective hydrogel scaffold, reinforced by a mechanical frame, specifically designed to facilitate the diffusion of insulin while effectively preventing the invasion of immune cells. This innovative biomaterial, comprised of 95% water, is synthesized using non-degradable polymers cross-linked by bio-orthogonal click chemistry.

This technology is protected via three patent applications4. Human islets encapsulated in AdoShell®? scaffold maintain, in vitro, a gluco-responsive insulin secretion comparable to naked islets.

The outcomes achieved by AdoShell®? Islets in preclinical trials hold true promises for people with T1D. This technology could not only obviate the need for immunosuppressive but also ensure extended functionality, and outstanding biocompatibility.

The potential of AdoShell®? Islet Islets could have a fundamental impact on the lives of millions of people living with diabetes and the way approach its treatment. AdoShell®?

is committed to advancing the development of AdoShell®?, making it one of its strategic priorities. Adocia is actively working towards initiating clinical trials to bring this technology to patients as quickly and safely as possible. Adocia is preparing interactions with the EMA (European Medicines Agency) to validate the proposed development plan.

AdoShell®?Islets could then be tested in clinics by the end of 2024. Preclinical data generated so far trigger interest from the scientific community and pharmaceutical industry. In parallel, AdoShell®?

scaff old, as a technology platform, is being considered for applications with stem cells and in other therapeutic areas (Parkinson disease, hemophilia, oncology, etc.). The physical barrier formed by AdoShell®? allows the implanted cells to be invisible to the host's immune system while allowing the necessary physiological exchanges to occur for the survival and function of the islets.

AdoShell®? Is lets is easily implantable through a minimally invasive surgery (laparoscopy) and is fullyretrievable. This biomaterial has demonstrated to be biocompatible and non-fibrotic.